Home > Press Releases > Radiopharmaceuticals Therapy Market

Radiopharmaceuticals Therapy Market Likely to Surpass ~USD 14 Billion by 2035

Report Code: HC-85580  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 434
Get PDF
Buy

Exploring novel growth opportunities on, “Radiopharmaceuticals Therapy Market Size, Share & Trends Analysis Report by Radioisotope Type (Alpha Emitters, Beta Emitters, Auger Emitters), Therapeutic Application, Product Type, Molecule Type, Source of Radioisotope, Route of Administration, Distribution Channel, Production Method, Technology Platform, Half-Life Duration, End-Users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A complete report exploring emerging market pathways in the radiopharmaceuticals therapy market illuminates revenue acceleration levers highlighting how scalable product line extensions, targeted new-market entries, and strategic partnerships are poised to drive top-line growth, expand market share.

Global Radiopharmaceuticals Therapy Market Forecast 2035:

According to the report, the global radiopharmaceuticals therapy market is likely to grow from USD 7.6 Billion in 2025 to USD 13.9 Billion in 2035 at a highest CAGR of 6.2% during the time period. The radiopharmaceuticals therapy market is growing due to the use of novel technologies, including AI-based drugs discovery platforms, predictive pharmacokinetic models, high-throughput isotope screens, computational radiochemistry and data-driven radioconjugate optimization. These innovations are helping pharmaceutical firms and research centers to increase the effects of therapeutics, accelerate the clinical development, target treatment of cancer and abnormal disease areas, and enhance the safety and consistency of radiopharmaceutical products.

New technologies in AI-assisted radioligand design, high-throughput isotope screening, precision PET/CT and SPECT imaging and dosimetry simulations are changing the global radiopharmaceuticals therapy market. Such technologies allow to identify the best radioligand-target pairs more quickly, tumor selectivity is enhanced, and pharmacokinetics and safety is improved. For instance, in July 2025, XtalPi and JingJiaHang BioPharma collaborated to further develop AI-based radionuclide drug development. The PepiX platform of XtalPi employs AI algorithms to quickly assemble and screen novel peptide ligands and accelerate the discovery of targeted therapy for oncology and neurodegenerative diseases and increase access to novel radiopharmaceuticals to more patients.

Additionally, major biotech and pharma firms are incorporating digital simulations, cloud-based analytics and automated production systems to simplify the radiopharmaceutical development and clinical translation processes. This integration of computer intelligence, experimental testing, and scalable production is facilitating more efficient, cost-effective and tailored therapies. Radiopharmaceuticals therapy market is being poised to a sustainable growth and a wider global implementation through synergies of innovative technologies, favorable regulatory framework and strategic alliances.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Radiopharmaceuticals Therapy Market”

The radiopharmaceuticals therapy market is increasingly moving towards personalised and precision-targeted therapy, particularly in oncology, neuroendocrine tumours and prostate cancers. By developing improvements in molecular imaging, biomarker discovery and theranostics, radiopharmaceuticals can be tailored to the tumor profile of an individual patient and allow more effective treatment with less off-target radiation. An example of a highly personalized treatment methodology is such alpha- and beta-emitter therapies whereby the treatment is confined to cancer cells and leaves normal tissue intact. They will probably guarantee the effectiveness of radiopharmaceutical therapies, their clinical applicability, and their patient-friendliness, eventually enhancing their results, and expanding their applicability to a variety of types of cancer.

Even with the advances, the market is constrained with low levels of awareness and uptake. The advantages of radiopharmaceuticals, including targeted therapy with low systemic toxicity and theranostic imaging, are not well known by many clinicians and patients. Misperception with reference to clinical outcome, off-target, or radiation safety may slow its adoption, particularly in areas of low healthcare literacy or very limited access to special centers.

Radiopharmaceuticals offer great growth opportunities as well, with favourable regulatory environments, public-private partnerships, and fast-track approvals. Innovation and commercialization are being promoted by governments and medical facilities giving out research grants, expedited approvals, and infrastructural assistance. Such efforts lower the cost of development, enhance accessibility of personalized treatment, and enable tailoring therapies to individual tumors, which would improve patient outcomes and speed up market penetration in the global market.

Impact of Tariff Rates on the global Radiopharmaceuticals Therapy Market

  • The global radiopharmaceuticals therapy market depends heavily on tariff rates as it dictates the price, accessibility and competitiveness of radiopharmaceutical products. Radioactive isotopes, raw materials or finished radiopharmaceuticals impose high import tariffs which can raise production costs which are usually transferred to the healthcare providers and patients, which may not be adopted in price sensitive markets. Lower or harmonized tariffs on the other hand facilitate the cross-border trade, which allows firms to enter into emerging markets like Asia-Pacific and Latin America.
  • The supply chain dynamics are also impacted by the tariffs because specialized isotopes such as Lutetium-177 and Actinium-225 are frequently sourced internationally; increased duty rates may delay the delivery speed of material and break clinical trials schedules. Pharmaceutical companies may be affected by regulatory and trade barriers coupled with tariff policies affecting investment choices, strategic alliances and entry strategies in the markets. In general, tariff rates are instrumental in determining the course of growth of the global market, pricing policies, and accessibility on a regional basis.

Regional Analysis of Global Radiopharmaceuticals Therapy Market

  • The North American radiopharmaceuticals therapy market has the highest rate in the worldwide market because of the established healthcare system, sophisticated molecular imaging units and strong awareness of the patients to the targeted therapies. The R&D in radiopharmaceuticals is actively encouraged by the government bodies and scientific organizations (like the U.S. National Institutes of Health (NIH) and the Canadian Health) via grants, funds, and partnership with the industry. In addition, the development of alpha-emitter, beta-emitter, theranostics, precision dosimetry, and AI-aided treatment planning, close regulatory backing, and an established pharmaceutical sector also solidify the position of North America in the global radiopharmaceuticals market.
  • Asia-Pacific radiopharmaceuticals therapy market is expected to have the highest growth rate in the world due to growing population, cancer and neuroendocrine tumor as well as rising incidence, urbanization, and growing access to advanced healthcare facilities in countries like China, India and Japan. The adoption of molecular imaging, theranostic systems, customized therapy methods, and positive government policies, combined with increasing biotech investments and increasing pharmaceutical production scale, represent the major drivers of the fast market growth in the region.

Prominent players operating in the global radiopharmaceuticals therapy market are Actinium Pharmaceuticals, Advanced Accelerator Applications (AAA) - Novartis, AstraZeneca, Bayer AG, Bristol Myers Squibb, Cardinal Health, Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler, Fusion Pharmaceuticals, GE HealthCare, Isotope Technologies Garching (ITG), Jubilant Pharma, Lantheus Holdings, Novartis AG, Perspective Therapeutics, POINT Biopharma, RadioMedix, RayzeBio (acquired by Bristol Myers Squibb), Revvity, Inc., Siemens Healthineers, Telix Pharmaceuticals, Other Key Players.

The global Radiopharmaceuticals Therapy market has been segmented as follows:

Global Radiopharmaceuticals Therapy Market Analysis, By Radioisotope Type

  • Alpha Emitters
    • Radium-223
    • Actinium-225
    • Lead-212
    • Bismuth-213
    • Astatine-211
  • Beta Emitters
    • Lutetium-177
    • Iodine-131
    • Yttrium-90
    • Samarium-153
    • Strontium-89
    • Rhenium-186
    • Rhenium-188
  • Auger Emitters
    • Iodine-125
    • Indium-111

Global Radiopharmaceuticals Therapy Market Analysis, By Therapeutic Application

  • Oncology
    • Prostate Cancer
    • Neuroendocrine Tumors (NETs)
    • Thyroid Cancer
    • Liver Cancer
    • Bone Metastases
    • Lymphoma
    • Brain Tumors
    • Others
  • Non-Oncology
    • Bone Pain Palliation
    • Rheumatoid Arthritis
    • Polycythemia Vera
    • Others

Global Radiopharmaceuticals Therapy Market Analysis, By Product Type

  • Targeted Radiopharmaceuticals
    • Peptide Receptor Radionuclide Therapy (PRRT)
    • Radioligand Therapy
    • Radioimmunotherapy
    • Others
  • Non-Targeted Radiopharmaceuticals
    • Selective Internal Radiation Therapy (SIRT)
    • Systemic Radiotherapy
    • Others

Global Radiopharmaceuticals Therapy Market Analysis, By Molecule Type

  • Small Molecules
  • Radioiodine
  • Radium Chloride
  • Biologics
  • Monoclonal Antibodies
  • Peptides
  • Aptamers

Global Radiopharmaceuticals Therapy Market Analysis, By Source of Radioisotope

  • Nuclear Reactors
  • Cyclotrons
  • Generators
  • Accelerators

Global Radiopharmaceuticals Therapy Market Analysis, By Route of Administration

  • Intravenous
  • Oral
  • Intra-arterial
  • Intracavitary
  • Intraperitoneal

Global Radiopharmaceuticals Therapy Market Analysis, By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Radiopharmaceuticals Therapy Market Analysis, By Production Method

  • Carrier-Added
  • No-Carrier-Added
  • Carrier-Free

Global Radiopharmaceuticals Therapy Market Analysis, By Technology Platform

  • Theranostics (Combination Diagnostic & Therapeutic)
  • Standalone Therapeutics
  • Companion Diagnostics-Guided Therapy

Global Radiopharmaceuticals Therapy Market Analysis, By Half-Life Duration

  • Short Half-Life (< 24 hours)
  • Medium Half-Life (1-10 days)
  • Long Half-Life (> 10 days)

Global Radiopharmaceuticals Therapy Market Analysis, By End-Users

  • Hospitals
  • Specialty Cancer Centers
  • Ambulatory Surgical Centers
  • Research & Academic Institutions
  • Nuclear Medicine Centers
  • Others

Global Radiopharmaceuticals Therapy Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Radiopharmaceuticals Therapy Market Outlook
      • 2.1.1. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare Industry Overview, 2025
      • 3.1.1. Healthcare Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare Industry
      • 3.1.3. Regional Distribution for Healthcare Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising prevalence of cancer and cardiovascular diseases driving demand for targeted radionuclide therapies.
        • 4.1.1.2. Advancements in radioisotope production and theranostic technologies enabling precise, personalized treatment approaches.
        • 4.1.1.3. Growing investments and strategic collaborations among pharma companies and CDMOs to expand isotope supply and GMP manufacturing capacity.
      • 4.1.2. Restraints
        • 4.1.2.1. Limited availability of medical radioisotopes (e.g., Lu-177, Ac-225) and complex production logistics.
        • 4.1.2.2. High production and infrastructure costs associated with regulatory compliance, radiation safety, and specialized facilities.
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Cost Structure Analysis
      • 4.5.1. Parameter’s Share for Cost Associated
      • 4.5.2. COGP vs COGS
      • 4.5.3. Profit Margin Analysis
    • 4.6. Pricing Analysis
      • 4.6.1. Regional Pricing Analysis
      • 4.6.2. Segmental Pricing Trends
      • 4.6.3. Factors Influencing Pricing
    • 4.7. Porter’s Five Forces Analysis
    • 4.8. PESTEL Analysis
    • 4.9. Global Radiopharmaceuticals Therapy Market Demand
      • 4.9.1. Historical Market Size –  Value (US$ Bn), 2020-2024
      • 4.9.2. Current and Future Market Size - Value (US$ Bn), 2025–2035
        • 4.9.2.1. Y-o-Y Growth Trends
        • 4.9.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Radiopharmaceuticals Therapy Market Analysis, by Radioisotope Type
    • 6.1. Key Segment Analysis
    • 6.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Radioisotope Type, 2021-2035
      • 6.2.1. Alpha Emitters
        • 6.2.1.1. Radium-223
        • 6.2.1.2. Actinium-225
        • 6.2.1.3. Lead-212
        • 6.2.1.4. Bismuth-213
        • 6.2.1.5. Astatine-211
      • 6.2.2. Beta Emitters
        • 6.2.2.1. Lutetium-177
        • 6.2.2.2. Iodine-131
        • 6.2.2.3. Yttrium-90
        • 6.2.2.4. Samarium-153
        • 6.2.2.5. Strontium-89
        • 6.2.2.6. Rhenium-186
        • 6.2.2.7. Rhenium-188
      • 6.2.3. Auger Emitters
        • 6.2.3.1. Iodine-125
        • 6.2.3.2. Indium-111
  • 7. Global Radiopharmaceuticals Therapy Market Analysis, by Therapeutic Application
    • 7.1. Key Segment Analysis
    • 7.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Application, 2021-2035
      • 7.2.1. Oncology
        • 7.2.1.1. Prostate Cancer
        • 7.2.1.2. Neuroendocrine Tumors (NETs)
        • 7.2.1.3. Thyroid Cancer
        • 7.2.1.4. Liver Cancer
        • 7.2.1.5. Bone Metastases
        • 7.2.1.6. Lymphoma
        • 7.2.1.7. Brain Tumors
        • 7.2.1.8. Others
      • 7.2.2. Non-Oncology
        • 7.2.2.1. Bone Pain Palliation
        • 7.2.2.2. Rheumatoid Arthritis
        • 7.2.2.3. Polycythemia Vera
        • 7.2.2.4. Others
  • 8. Global Radiopharmaceuticals Therapy Market Analysis, by Product Type
    • 8.1. Key Segment Analysis
    • 8.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Product Type, 2021-2035
      • 8.2.1. Targeted Radiopharmaceuticals
        • 8.2.1.1. Peptide Receptor Radionuclide Therapy (PRRT)
        • 8.2.1.2. Radioligand Therapy
        • 8.2.1.3. Radioimmunotherapy
        • 8.2.1.4. Others
      • 8.2.2. Non-Targeted Radiopharmaceuticals
        • 8.2.2.1. Selective Internal Radiation Therapy (SIRT)
        • 8.2.2.2. Systemic Radiotherapy
        • 8.2.2.3. Others
  • 9. Global Radiopharmaceuticals Therapy Market Analysis, by Molecule Type
    • 9.1. Key Segment Analysis
    • 9.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecule Type, 2021-2035
      • 9.2.1. Small Molecules
        • 9.2.1.1. Radioiodine
        • 9.2.1.2. Radium Chloride
      • 9.2.2. Biologics
        • 9.2.2.1. Monoclonal Antibodies
        • 9.2.2.2. Peptides
        • 9.2.2.3. Aptamers
  • 10. Global Radiopharmaceuticals Therapy Market Analysis, by Source of Radioisotope
    • 10.1. Key Segment Analysis
    • 10.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Source of Radioisotope, 2021-2035
      • 10.2.1. Nuclear Reactors
      • 10.2.2. Cyclotrons
      • 10.2.3. Generators
      • 10.2.4. Accelerators
  • 11. Global Radiopharmaceuticals Therapy Market Analysis, by Route of Administration
    • 11.1. Key Segment Analysis
    • 11.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
      • 11.2.1. Intravenous
      • 11.2.2. Oral
      • 11.2.3. Intra-arterial
      • 11.2.4. Intracavitary
      • 11.2.5. Intraperitoneal
  • 12. Global Radiopharmaceuticals Therapy Market Analysis, by Distribution Channel
    • 12.1. Key Segment Analysis
    • 12.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 12.2.1. Hospital Pharmacies
      • 12.2.2. Specialty Pharmacies
      • 12.2.3. Retail Pharmacies
      • 12.2.4. Online Pharmacies
  • 13. Global Radiopharmaceuticals Therapy Market Analysis, by Production Method
    • 13.1. Key Segment Analysis
    • 13.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Production Method, 2021-2035
      • 13.2.1. Carrier-Added
      • 13.2.2. No-Carrier-Added
      • 13.2.3. Carrier-Free
  • 14. Global Radiopharmaceuticals Therapy Market Analysis, by Technology Platform
    • 14.1. Key Segment Analysis
    • 14.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology Platform, 2021-2035
      • 14.2.1. Theranostics (Combination Diagnostic & Therapeutic)
      • 14.2.2. Standalone Therapeutics
      • 14.2.3. Companion Diagnostics-Guided Therapy
  • 15. Global Radiopharmaceuticals Therapy Market Analysis, by Half-Life Duration
    • 15.1. Key Segment Analysis
    • 15.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Half-Life Duration, 2021-2035
      • 15.2.1. Short Half-Life (< 24 hours)
      • 15.2.2. Medium Half-Life (1-10 days)
      • 15.2.3. Long Half-Life (> 10 days)
  • 16. Global Radiopharmaceuticals Therapy Market Analysis, by End-Users
    • 16.1. Key Segment Analysis
    • 16.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-Users, 2021-2035
      • 16.2.1. Hospitals
      • 16.2.2. Specialty Cancer Centers
      • 16.2.3. Ambulatory Surgical Centers
      • 16.2.4. Research & Academic Institutions
      • 16.2.5. Nuclear Medicine Centers
      • 16.2.6. Others
  • 17. Global Radiopharmaceuticals Therapy Market Analysis and Forecasts, by Region
    • 17.1. Key Findings
    • 17.2. Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 17.2.1. North America
      • 17.2.2. Europe
      • 17.2.3. Asia Pacific
      • 17.2.4. Middle East
      • 17.2.5. Africa
      • 17.2.6. South America
  • 18. North America Radiopharmaceuticals Therapy Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. North America Radiopharmaceuticals Therapy Market Size Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Radioisotope Type
      • 18.3.2. Therapeutic Application
      • 18.3.3. Product Type
      • 18.3.4. Molecule Type
      • 18.3.5. Source of Radioisotope
      • 18.3.6. Route of Administration
      • 18.3.7. Distribution Channel
      • 18.3.8. Production Method
      • 18.3.9. Technology Platform
      • 18.3.10. Half-Life Duration
      • 18.3.11. End-Users
      • 18.3.12. Country
        • 18.3.12.1. USA
        • 18.3.12.2. Canada
        • 18.3.12.3. Mexico
    • 18.4. USA Radiopharmaceuticals Therapy Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Radioisotope Type
      • 18.4.3. Therapeutic Application
      • 18.4.4. Product Type
      • 18.4.5. Molecule Type
      • 18.4.6. Source of Radioisotope
      • 18.4.7. Route of Administration
      • 18.4.8. Distribution Channel
      • 18.4.9. Production Method
      • 18.4.10. Technology Platform
      • 18.4.11. Half-Life Duration
      • 18.4.12. End-Users
    • 18.5. Canada Radiopharmaceuticals Therapy Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Radioisotope Type
      • 18.5.3. Therapeutic Application
      • 18.5.4. Product Type
      • 18.5.5. Molecule Type
      • 18.5.6. Source of Radioisotope
      • 18.5.7. Route of Administration
      • 18.5.8. Distribution Channel
      • 18.5.9. Production Method
      • 18.5.10. Technology Platform
      • 18.5.11. Half-Life Duration
      • 18.5.12. End-Users
    • 18.6. Mexico Radiopharmaceuticals Therapy Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Radioisotope Type
      • 18.6.3. Therapeutic Application
      • 18.6.4. Product Type
      • 18.6.5. Molecule Type
      • 18.6.6. Source of Radioisotope
      • 18.6.7. Route of Administration
      • 18.6.8. Distribution Channel
      • 18.6.9. Production Method
      • 18.6.10. Technology Platform
      • 18.6.11. Half-Life Duration
      • 18.6.12. End-Users
  • 19. Europe Radiopharmaceuticals Therapy Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Europe Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Radioisotope Type
      • 19.3.2. Therapeutic Application
      • 19.3.3. Product Type
      • 19.3.4. Molecule Type
      • 19.3.5. Source of Radioisotope
      • 19.3.6. Route of Administration
      • 19.3.7. Distribution Channel
      • 19.3.8. Production Method
      • 19.3.9. Technology Platform
      • 19.3.10. Half-Life Duration
      • 19.3.11. End-Users
      • 19.3.12. Country
        • 19.3.12.1. Germany
        • 19.3.12.2. United Kingdom
        • 19.3.12.3. France
        • 19.3.12.4. Italy
        • 19.3.12.5. Spain
        • 19.3.12.6. Netherlands
        • 19.3.12.7. Nordic Countries
        • 19.3.12.8. Poland
        • 19.3.12.9. Russia & CIS
        • 19.3.12.10. Rest of Europe
    • 19.4. Germany Radiopharmaceuticals Therapy Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Radioisotope Type
      • 19.4.3. Therapeutic Application
      • 19.4.4. Product Type
      • 19.4.5. Molecule Type
      • 19.4.6. Source of Radioisotope
      • 19.4.7. Route of Administration
      • 19.4.8. Distribution Channel
      • 19.4.9. Production Method
      • 19.4.10. Technology Platform
      • 19.4.11. Half-Life Duration
      • 19.4.12. End-Users
    • 19.5. United Kingdom Radiopharmaceuticals Therapy Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Radioisotope Type
      • 19.5.3. Therapeutic Application
      • 19.5.4. Product Type
      • 19.5.5. Molecule Type
      • 19.5.6. Source of Radioisotope
      • 19.5.7. Route of Administration
      • 19.5.8. Distribution Channel
      • 19.5.9. Production Method
      • 19.5.10. Technology Platform
      • 19.5.11. Half-Life Duration
      • 19.5.12. End-Users
    • 19.6. France Radiopharmaceuticals Therapy Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Radioisotope Type
      • 19.6.3. Therapeutic Application
      • 19.6.4. Product Type
      • 19.6.5. Molecule Type
      • 19.6.6. Source of Radioisotope
      • 19.6.7. Route of Administration
      • 19.6.8. Distribution Channel
      • 19.6.9. Production Method
      • 19.6.10. Technology Platform
      • 19.6.11. Half-Life Duration
      • 19.6.12. End-Users
    • 19.7. Italy Radiopharmaceuticals Therapy Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Radioisotope Type
      • 19.7.3. Therapeutic Application
      • 19.7.4. Product Type
      • 19.7.5. Molecule Type
      • 19.7.6. Source of Radioisotope
      • 19.7.7. Route of Administration
      • 19.7.8. Distribution Channel
      • 19.7.9. Production Method
      • 19.7.10. Technology Platform
      • 19.7.11. Half-Life Duration
      • 19.7.12. End-Users
    • 19.8. Spain Radiopharmaceuticals Therapy Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Radioisotope Type
      • 19.8.3. Therapeutic Application
      • 19.8.4. Product Type
      • 19.8.5. Molecule Type
      • 19.8.6. Source of Radioisotope
      • 19.8.7. Route of Administration
      • 19.8.8. Distribution Channel
      • 19.8.9. Production Method
      • 19.8.10. Technology Platform
      • 19.8.11. Half-Life Duration
      • 19.8.12. End-Users
    • 19.9. Netherlands Radiopharmaceuticals Therapy Market
      • 19.9.1. Country Segmental Analysis
      • 19.9.2. Radioisotope Type
      • 19.9.3. Therapeutic Application
      • 19.9.4. Product Type
      • 19.9.5. Molecule Type
      • 19.9.6. Source of Radioisotope
      • 19.9.7. Route of Administration
      • 19.9.8. Distribution Channel
      • 19.9.9. Production Method
      • 19.9.10. Technology Platform
      • 19.9.11. Half-Life Duration
      • 19.9.12. End-Users
    • 19.10. Nordic Countries Radiopharmaceuticals Therapy Market
      • 19.10.1. Country Segmental Analysis
      • 19.10.2. Radioisotope Type
      • 19.10.3. Therapeutic Application
      • 19.10.4. Product Type
      • 19.10.5. Molecule Type
      • 19.10.6. Source of Radioisotope
      • 19.10.7. Route of Administration
      • 19.10.8. Distribution Channel
      • 19.10.9. Production Method
      • 19.10.10. Technology Platform
      • 19.10.11. Half-Life Duration
      • 19.10.12. End-Users
    • 19.11. Poland Radiopharmaceuticals Therapy Market
      • 19.11.1. Country Segmental Analysis
      • 19.11.2. Radioisotope Type
      • 19.11.3. Therapeutic Application
      • 19.11.4. Product Type
      • 19.11.5. Molecule Type
      • 19.11.6. Source of Radioisotope
      • 19.11.7. Route of Administration
      • 19.11.8. Distribution Channel
      • 19.11.9. Production Method
      • 19.11.10. Technology Platform
      • 19.11.11. Half-Life Duration
      • 19.11.12. End-Users
    • 19.12. Russia & CIS Radiopharmaceuticals Therapy Market
      • 19.12.1. Country Segmental Analysis
      • 19.12.2. Radioisotope Type
      • 19.12.3. Therapeutic Application
      • 19.12.4. Product Type
      • 19.12.5. Molecule Type
      • 19.12.6. Source of Radioisotope
      • 19.12.7. Route of Administration
      • 19.12.8. Distribution Channel
      • 19.12.9. Production Method
      • 19.12.10. Technology Platform
      • 19.12.11. Half-Life Duration
      • 19.12.12. End-Users
    • 19.13. Rest of Europe Radiopharmaceuticals Therapy Market
      • 19.13.1. Country Segmental Analysis
      • 19.13.2. Radioisotope Type
      • 19.13.3. Therapeutic Application
      • 19.13.4. Product Type
      • 19.13.5. Molecule Type
      • 19.13.6. Source of Radioisotope
      • 19.13.7. Route of Administration
      • 19.13.8. Distribution Channel
      • 19.13.9. Production Method
      • 19.13.10. Technology Platform
      • 19.13.11. Half-Life Duration
      • 19.13.12. End-Users
  • 20. Asia Pacific Radiopharmaceuticals Therapy Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. East Asia Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Radioisotope Type
      • 20.3.2. Therapeutic Application
      • 20.3.3. Product Type
      • 20.3.4. Molecule Type
      • 20.3.5. Source of Radioisotope
      • 20.3.6. Route of Administration
      • 20.3.7. Distribution Channel
      • 20.3.8. Production Method
      • 20.3.9. Technology Platform
      • 20.3.10. Half-Life Duration
      • 20.3.11. End-Users
      • 20.3.12. Country
        • 20.3.12.1. China
        • 20.3.12.2. India
        • 20.3.12.3. Japan
        • 20.3.12.4. South Korea
        • 20.3.12.5. Australia and New Zealand
        • 20.3.12.6. Indonesia
        • 20.3.12.7. Malaysia
        • 20.3.12.8. Thailand
        • 20.3.12.9. Vietnam
        • 20.3.12.10. Rest of Asia Pacific
    • 20.4. China Radiopharmaceuticals Therapy Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Radioisotope Type
      • 20.4.3. Therapeutic Application
      • 20.4.4. Product Type
      • 20.4.5. Molecule Type
      • 20.4.6. Source of Radioisotope
      • 20.4.7. Route of Administration
      • 20.4.8. Distribution Channel
      • 20.4.9. Production Method
      • 20.4.10. Technology Platform
      • 20.4.11. Half-Life Duration
      • 20.4.12. End-Users
    • 20.5. India Radiopharmaceuticals Therapy Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Radioisotope Type
      • 20.5.3. Therapeutic Application
      • 20.5.4. Product Type
      • 20.5.5. Molecule Type
      • 20.5.6. Source of Radioisotope
      • 20.5.7. Route of Administration
      • 20.5.8. Distribution Channel
      • 20.5.9. Production Method
      • 20.5.10. Technology Platform
      • 20.5.11. Half-Life Duration
      • 20.5.12. End-Users
    • 20.6. Japan Radiopharmaceuticals Therapy Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Radioisotope Type
      • 20.6.3. Therapeutic Application
      • 20.6.4. Product Type
      • 20.6.5. Molecule Type
      • 20.6.6. Source of Radioisotope
      • 20.6.7. Route of Administration
      • 20.6.8. Distribution Channel
      • 20.6.9. Production Method
      • 20.6.10. Technology Platform
      • 20.6.11. Half-Life Duration
      • 20.6.12. End-Users
    • 20.7. South Korea Radiopharmaceuticals Therapy Market
      • 20.7.1. Country Segmental Analysis
      • 20.7.2. Radioisotope Type
      • 20.7.3. Therapeutic Application
      • 20.7.4. Product Type
      • 20.7.5. Molecule Type
      • 20.7.6. Source of Radioisotope
      • 20.7.7. Route of Administration
      • 20.7.8. Distribution Channel
      • 20.7.9. Production Method
      • 20.7.10. Technology Platform
      • 20.7.11. Half-Life Duration
      • 20.7.12. End-Users
    • 20.8. Australia and New Zealand Radiopharmaceuticals Therapy Market
      • 20.8.1. Country Segmental Analysis
      • 20.8.2. Radioisotope Type
      • 20.8.3. Therapeutic Application
      • 20.8.4. Product Type
      • 20.8.5. Molecule Type
      • 20.8.6. Source of Radioisotope
      • 20.8.7. Route of Administration
      • 20.8.8. Distribution Channel
      • 20.8.9. Production Method
      • 20.8.10. Technology Platform
      • 20.8.11. Half-Life Duration
      • 20.8.12. End-Users
    • 20.9. Indonesia Radiopharmaceuticals Therapy Market
      • 20.9.1. Country Segmental Analysis
      • 20.9.2. Radioisotope Type
      • 20.9.3. Therapeutic Application
      • 20.9.4. Product Type
      • 20.9.5. Molecule Type
      • 20.9.6. Source of Radioisotope
      • 20.9.7. Route of Administration
      • 20.9.8. Distribution Channel
      • 20.9.9. Production Method
      • 20.9.10. Technology Platform
      • 20.9.11. Half-Life Duration
      • 20.9.12. End-Users
    • 20.10. Malaysia Radiopharmaceuticals Therapy Market
      • 20.10.1. Country Segmental Analysis
      • 20.10.2. Radioisotope Type
      • 20.10.3. Therapeutic Application
      • 20.10.4. Product Type
      • 20.10.5. Molecule Type
      • 20.10.6. Source of Radioisotope
      • 20.10.7. Route of Administration
      • 20.10.8. Distribution Channel
      • 20.10.9. Production Method
      • 20.10.10. Technology Platform
      • 20.10.11. Half-Life Duration
      • 20.10.12. End-Users
    • 20.11. Thailand Radiopharmaceuticals Therapy Market
      • 20.11.1. Country Segmental Analysis
      • 20.11.2. Radioisotope Type
      • 20.11.3. Therapeutic Application
      • 20.11.4. Product Type
      • 20.11.5. Molecule Type
      • 20.11.6. Source of Radioisotope
      • 20.11.7. Route of Administration
      • 20.11.8. Distribution Channel
      • 20.11.9. Production Method
      • 20.11.10. Technology Platform
      • 20.11.11. Half-Life Duration
      • 20.11.12. End-Users
    • 20.12. Vietnam Radiopharmaceuticals Therapy Market
      • 20.12.1. Country Segmental Analysis
      • 20.12.2. Radioisotope Type
      • 20.12.3. Therapeutic Application
      • 20.12.4. Product Type
      • 20.12.5. Molecule Type
      • 20.12.6. Source of Radioisotope
      • 20.12.7. Route of Administration
      • 20.12.8. Distribution Channel
      • 20.12.9. Production Method
      • 20.12.10. Technology Platform
      • 20.12.11. Half-Life Duration
      • 20.12.12. End-Users
    • 20.13. Rest of Asia Pacific Radiopharmaceuticals Therapy Market
      • 20.13.1. Country Segmental Analysis
      • 20.13.2. Radioisotope Type
      • 20.13.3. Therapeutic Application
      • 20.13.4. Product Type
      • 20.13.5. Molecule Type
      • 20.13.6. Source of Radioisotope
      • 20.13.7. Route of Administration
      • 20.13.8. Distribution Channel
      • 20.13.9. Production Method
      • 20.13.10. Technology Platform
      • 20.13.11. Half-Life Duration
      • 20.13.12. End-Users
  • 21. Middle East Radiopharmaceuticals Therapy Market Analysis
    • 21.1. Key Segment Analysis
    • 21.2. Regional Snapshot
    • 21.3. Middle East Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 21.3.1. Radioisotope Type
      • 21.3.2. Therapeutic Application
      • 21.3.3. Product Type
      • 21.3.4. Molecule Type
      • 21.3.5. Source of Radioisotope
      • 21.3.6. Route of Administration
      • 21.3.7. Distribution Channel
      • 21.3.8. Production Method
      • 21.3.9. Technology Platform
      • 21.3.10. Half-Life Duration
      • 21.3.11. End-Users
      • 21.3.12. Country
        • 21.3.12.1. Turkey
        • 21.3.12.2. UAE
        • 21.3.12.3. Saudi Arabia
        • 21.3.12.4. Israel
        • 21.3.12.5. Rest of Middle East
    • 21.4. Turkey Radiopharmaceuticals Therapy Market
      • 21.4.1. Country Segmental Analysis
      • 21.4.2. Radioisotope Type
      • 21.4.3. Therapeutic Application
      • 21.4.4. Product Type
      • 21.4.5. Molecule Type
      • 21.4.6. Source of Radioisotope
      • 21.4.7. Route of Administration
      • 21.4.8. Distribution Channel
      • 21.4.9. Production Method
      • 21.4.10. Technology Platform
      • 21.4.11. Half-Life Duration
      • 21.4.12. End-Users
    • 21.5. UAE Radiopharmaceuticals Therapy Market
      • 21.5.1. Country Segmental Analysis
      • 21.5.2. Radioisotope Type
      • 21.5.3. Therapeutic Application
      • 21.5.4. Product Type
      • 21.5.5. Molecule Type
      • 21.5.6. Source of Radioisotope
      • 21.5.7. Route of Administration
      • 21.5.8. Distribution Channel
      • 21.5.9. Production Method
      • 21.5.10. Technology Platform
      • 21.5.11. Half-Life Duration
      • 21.5.12. End-Users
    • 21.6. Saudi Arabia Radiopharmaceuticals Therapy Market
      • 21.6.1. Country Segmental Analysis
      • 21.6.2. Radioisotope Type
      • 21.6.3. Therapeutic Application
      • 21.6.4. Product Type
      • 21.6.5. Molecule Type
      • 21.6.6. Source of Radioisotope
      • 21.6.7. Route of Administration
      • 21.6.8. Distribution Channel
      • 21.6.9. Production Method
      • 21.6.10. Technology Platform
      • 21.6.11. Half-Life Duration
      • 21.6.12. End-Users
    • 21.7. Israel Radiopharmaceuticals Therapy Market
      • 21.7.1. Country Segmental Analysis
      • 21.7.2. Radioisotope Type
      • 21.7.3. Therapeutic Application
      • 21.7.4. Product Type
      • 21.7.5. Molecule Type
      • 21.7.6. Source of Radioisotope
      • 21.7.7. Route of Administration
      • 21.7.8. Distribution Channel
      • 21.7.9. Production Method
      • 21.7.10. Technology Platform
      • 21.7.11. Half-Life Duration
      • 21.7.12. End-Users
    • 21.8. Rest of Middle East Radiopharmaceuticals Therapy Market
      • 21.8.1. Country Segmental Analysis
      • 21.8.2. Radioisotope Type
      • 21.8.3. Therapeutic Application
      • 21.8.4. Product Type
      • 21.8.5. Molecule Type
      • 21.8.6. Source of Radioisotope
      • 21.8.7. Route of Administration
      • 21.8.8. Distribution Channel
      • 21.8.9. Production Method
      • 21.8.10. Technology Platform
      • 21.8.11. Half-Life Duration
      • 21.8.12. End-Users
  • 22. Africa Radiopharmaceuticals Therapy Market Analysis
    • 22.1. Key Segment Analysis
    • 22.2. Regional Snapshot
    • 22.3. Africa Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 22.3.1. Radioisotope Type
      • 22.3.2. Therapeutic Application
      • 22.3.3. Product Type
      • 22.3.4. Molecule Type
      • 22.3.5. Source of Radioisotope
      • 22.3.6. Route of Administration
      • 22.3.7. Distribution Channel
      • 22.3.8. Production Method
      • 22.3.9. Technology Platform
      • 22.3.10. Half-Life Duration
      • 22.3.11. End-Users
      • 22.3.12. Country
        • 22.3.12.1. South Africa
        • 22.3.12.2. Egypt
        • 22.3.12.3. Nigeria
        • 22.3.12.4. Algeria
        • 22.3.12.5. Rest of Africa
    • 22.4. South Africa Radiopharmaceuticals Therapy Market
      • 22.4.1. Country Segmental Analysis
      • 22.4.2. Radioisotope Type
      • 22.4.3. Therapeutic Application
      • 22.4.4. Product Type
      • 22.4.5. Molecule Type
      • 22.4.6. Source of Radioisotope
      • 22.4.7. Route of Administration
      • 22.4.8. Distribution Channel
      • 22.4.9. Production Method
      • 22.4.10. Technology Platform
      • 22.4.11. Half-Life Duration
      • 22.4.12. End-Users
    • 22.5. Egypt Radiopharmaceuticals Therapy Market
      • 22.5.1. Country Segmental Analysis
      • 22.5.2. Radioisotope Type
      • 22.5.3. Therapeutic Application
      • 22.5.4. Product Type
      • 22.5.5. Molecule Type
      • 22.5.6. Source of Radioisotope
      • 22.5.7. Route of Administration
      • 22.5.8. Distribution Channel
      • 22.5.9. Production Method
      • 22.5.10. Technology Platform
      • 22.5.11. Half-Life Duration
      • 22.5.12. End-Users
    • 22.6. Nigeria Radiopharmaceuticals Therapy Market
      • 22.6.1. Country Segmental Analysis
      • 22.6.2. Radioisotope Type
      • 22.6.3. Therapeutic Application
      • 22.6.4. Product Type
      • 22.6.5. Molecule Type
      • 22.6.6. Source of Radioisotope
      • 22.6.7. Route of Administration
      • 22.6.8. Distribution Channel
      • 22.6.9. Production Method
      • 22.6.10. Technology Platform
      • 22.6.11. Half-Life Duration
      • 22.6.12. End-Users
    • 22.7. Algeria Radiopharmaceuticals Therapy Market
      • 22.7.1. Country Segmental Analysis
      • 22.7.2. Radioisotope Type
      • 22.7.3. Therapeutic Application
      • 22.7.4. Product Type
      • 22.7.5. Molecule Type
      • 22.7.6. Source of Radioisotope
      • 22.7.7. Route of Administration
      • 22.7.8. Distribution Channel
      • 22.7.9. Production Method
      • 22.7.10. Technology Platform
      • 22.7.11. Half-Life Duration
      • 22.7.12. End-Users
    • 22.8. Rest of Africa Radiopharmaceuticals Therapy Market
      • 22.8.1. Country Segmental Analysis
      • 22.8.2. Radioisotope Type
      • 22.8.3. Therapeutic Application
      • 22.8.4. Product Type
      • 22.8.5. Molecule Type
      • 22.8.6. Source of Radioisotope
      • 22.8.7. Route of Administration
      • 22.8.8. Distribution Channel
      • 22.8.9. Production Method
      • 22.8.10. Technology Platform
      • 22.8.11. Half-Life Duration
      • 22.8.12. End-Users
  • 23. South America Radiopharmaceuticals Therapy Market Analysis
    • 23.1. Key Segment Analysis
    • 23.2. Regional Snapshot
    • 23.3. Central and South Africa Radiopharmaceuticals Therapy Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 23.3.1. Radioisotope Type
      • 23.3.2. Therapeutic Application
      • 23.3.3. Product Type
      • 23.3.4. Molecule Type
      • 23.3.5. Source of Radioisotope
      • 23.3.6. Route of Administration
      • 23.3.7. Distribution Channel
      • 23.3.8. Production Method
      • 23.3.9. Technology Platform
      • 23.3.10. Half-Life Duration
      • 23.3.11. End-Users
      • 23.3.12. Country
        • 23.3.12.1. Brazil
        • 23.3.12.2. Argentina
        • 23.3.12.3. Rest of South America
    • 23.4. Brazil Radiopharmaceuticals Therapy Market
      • 23.4.1. Country Segmental Analysis
      • 23.4.2. Radioisotope Type
      • 23.4.3. Therapeutic Application
      • 23.4.4. Product Type
      • 23.4.5. Molecule Type
      • 23.4.6. Source of Radioisotope
      • 23.4.7. Route of Administration
      • 23.4.8. Distribution Channel
      • 23.4.9. Production Method
      • 23.4.10. Technology Platform
      • 23.4.11. Half-Life Duration
      • 23.4.12. End-Users
    • 23.5. Argentina Radiopharmaceuticals Therapy Market
      • 23.5.1. Country Segmental Analysis
      • 23.5.2. Radioisotope Type
      • 23.5.3. Therapeutic Application
      • 23.5.4. Product Type
      • 23.5.5. Molecule Type
      • 23.5.6. Source of Radioisotope
      • 23.5.7. Route of Administration
      • 23.5.8. Distribution Channel
      • 23.5.9. Production Method
      • 23.5.10. Technology Platform
      • 23.5.11. Half-Life Duration
      • 23.5.12. End-Users
    • 23.6. Rest of South America Radiopharmaceuticals Therapy Market
      • 23.6.1. Country Segmental Analysis
      • 23.6.2. Radioisotope Type
      • 23.6.3. Therapeutic Application
      • 23.6.4. Product Type
      • 23.6.5. Molecule Type
      • 23.6.6. Source of Radioisotope
      • 23.6.7. Route of Administration
      • 23.6.8. Distribution Channel
      • 23.6.9. Production Method
      • 23.6.10. Technology Platform
      • 23.6.11. Half-Life Duration
      • 23.6.12. End-Users
  • 24. Key Players/ Company Profile
    • 24.1. Actinium Pharmaceuticals
      • 24.1.1. Company Details/ Overview
      • 24.1.2. Company Financials
      • 24.1.3. Key Customers and Competitors
      • 24.1.4. Business/ Industry Portfolio
      • 24.1.5. Product Portfolio/ Specification Details
      • 24.1.6. Pricing Data
      • 24.1.7. Strategic Overview
      • 24.1.8. Recent Developments
    • 24.2. Advanced Accelerator Applications (AAA) - Novartis
    • 24.3. AstraZeneca
    • 24.4. Bayer AG
    • 24.5. Bristol Myers Squibb
    • 24.6. Cardinal Health
    • 24.7. Clarity Pharmaceuticals
    • 24.8. Curium Pharma
    • 24.9. Eckert & Ziegler
    • 24.10. Fusion Pharmaceuticals
    • 24.11. GE HealthCare
    • 24.12. Isotope Technologies Garching (ITG)
    • 24.13. Jubilant Pharma
    • 24.14. Lantheus Holdings
    • 24.15. Novartis AG
    • 24.16. Perspective Therapeutics
    • 24.17. POINT Biopharma
    • 24.18. RadioMedix
    • 24.19. RayzeBio (acquired by Bristol Myers Squibb)
    • 24.20. Revvity, Inc.
    • 24.21. Siemens Healthineers
    • 24.22. Telix Pharmaceuticals
    • 24.23. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation